No Effect of Methylnaltrexone on Acute Pancreatitis Severity: A Multicenter Randomized Controlled Trial
Cecilie Siggaard Knoph,Mathias Ellgaard Cook,Srdan Novovic,Mark Berner Hansen,Michael Bau Mortensen,Liv Bjerre Juul Nielsen,Irene Maria Høgsberg,Celina Salomon,Celine Emilie Lindqvist Neergaard,Aseel Jabbar Aajwad,Sanjay Pandanaboyana,Lone Schmidt Sørensen,Ole Thorlacius-Ussing,Jens Brøndum Frøkjær,Søren Schou Olesen,Asbjørn Mohr Drewes
DOI: https://doi.org/10.14309/ajg.0000000000002904
2024-06-27
The American Journal of Gastroenterology
Abstract:Objectives: Opioids used to manage severe pain in acute pancreatitis might exacerbate the disease through effects on gastrointestinal and immune functions. Methylnaltrexone, a peripherally acting μ-opioid receptor antagonist, may counteract these effects without changing analgesia. Methods: This double-blind, randomized, placebo-controlled trial included adult patients with acute pancreatitis and systemic inflammatory response syndrome at four Danish centers. Participants were randomized to receive five days of continuous intravenous methylnaltrexone (0.15mg/kg/day) or placebo added to the standard of care. The primary endpoint was the Pancreatitis Activity Scoring System score after 48 hours of treatment. Main secondary outcomes included pain scores, opioid use, disease severity, and mortality. Results: In total, 105 patients (54% males) were randomized to methylnaltrexone (n=51) or placebo (n=54). After 48 hours, the Pancreatitis Activity Scoring System score was 134.3 points in the methylnaltrexone group and 130.5 points in the placebo group (difference, 3.8 [95% CI, -40.1 to 47.6]; P=0.87). At 48 hours, we found no differences between groups in pain severity (0.0 [95% CI, -0.8 to 0.9]; P=0.94), pain interference (-0.3 [95% CI, -1.4 to 0.8]; P=0.55), and morphine equivalent doses (6.5 mg [95% CI, -2.1 to 15.2]; P=0.14). Methylnaltrexone also did not affect the risk of severe disease (8% [95% CI, -11 to 28]; P=0.38) and mortality (6% [95% CI, -1 to 12]; P=0.11). The medication was well-tolerated. Conclusions: Methylnaltrexone treatment did not achieve superiority over placebo for reducing the severity of acute pancreatitis.
gastroenterology & hepatology